Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies

被引：1

作者：

Arasanz, Hugo ^{[1
,2
]}

Zuazo, Miren ^{[1
]}

Vera, Ruth ^{[2
]}

Kochan, Grazyna ^{[1
]}

Escors, David ^{[1
,3
]}

机构：

[1] CHN, IdISNA, Immunomodulat Grp, Navarrabiomed Fdn Miguel Servet, Irunlarrea 3, Navarra 31008, Spain

[2] CHN, Dept Oncol, Irunlarrea 3, Navarra 31008, Spain

[3] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England

来源：

LUNG CANCER MANAGEMENT | 2018年 / 7卷 / 03期

关键词：

B7-H1; biomarker; immune checkpoint blockade; NSCLC; PD-1; PD-L1; T lymphocyte;

D O I：

10.2217/lmt-2018-0014

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：4

共 17 条

[1]

[Anonymous], 2018, J BIORXIV, DOI DOI 10.1101/320176

[2] Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis [J].

Benedict Sacdalan, Danielle ;

Anne Lucero, Josephine ;

Lee Sacdalan, Dennis .

ONCOTARGETS AND THERAPY, 2018, 11 :955-965

[3] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[4] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[5] PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity [J].

Gato-Canas, Maria ;

Zuazo, Miren ;

Arasanz, Hugo ;

Ibanez-Vea, Maria ;

Lorenzo, Laura ;

Fernandez-Hinojal, Gonzalo ;

Vera, Ruth ;

Smerdou, Cristian ;

Martisova, Eva ;

Arozarena, Imanol ;

Wellbrock, Claudia ;

Llopiz, Diana ;

Ruiz, Marta ;

Sarobe, Pablo ;

Breckpot, Karine ;

Kochan, Grazyna ;

Escors, David .

CELL REPORTS, 2017, 20 (08) :1818-1829

[6] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[7] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[8] Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J].

Horn, Leora ;

Spigel, David R. ;

Vokes, Everett E. ;

Holgado, Esther ;

Ready, Neal ;

Steins, Martin ;

Poddubskaya, Elena ;

Borghaei, Hossein ;

Felip, Enriqueta ;

Paz-Ares, Luis ;

Pluzanski, Adam ;

Reckamp, Karen L. ;

Burgio, Marco A. ;

Kohlhaeeufl, Martin ;

Waterhouse, David ;

Barlesi, Fabrice ;

Antonia, Scott ;

Arrieta, Oscar ;

Fayette, Jerome ;

Crino, Lucio ;

Rizvi, Naiyer ;

Reck, Martin ;

Hellmann, Matthew D. ;

Geese, William J. ;

Li, Ang ;

Blackwood-Chirchir, Anne ;

Healey, Diane ;

Brahmer, Julie ;

Eberhardt, Wilfried E. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) :3924-+

[9] Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients [J].

Kamphorst, Alice O. ;

Pillai, Rathi N. ;

Yang, Shu ;

Nasti, Tahseen H. ;

Akondy, Rama S. ;

Wieland, Andreas ;

Sica, Gabriel L. ;

Yu, Ke ;

Koenig, Lydia ;

Patel, Nikita T. ;

Behera, Madhusmita ;

Wu, Hong ;

McCausland, Megan ;

Chen, Zhengjia ;

Zhang, Chao ;

Khuri, Fadlo R. ;

Owonikoko, Taofeek K. ;

Ahmed, Rafi ;

Ramalingam, Suresh S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (19) :4993-4998

[10] PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells [J].

Karwacz, Katarzyna ;

Bricogne, Christopher ;

MacDonald, Douglas ;

Arce, Frederick ;

Bennett, Clare L. ;

Collins, Mary ;

Escors, David .

EMBO MOLECULAR MEDICINE, 2011, 3 (10) :581-592

← 1 2 →